Companies › Intensity Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INT230-6 Fixed combination of cisplatin, vinblastine and SHAO; intratumoral injection | – | Phase 3 | Sarcoma,Soft Tissue; Triple-negative Breast Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06263231 | INT230-6 | Phase 3 | Sarcoma,Soft Tissue | Oncology | Dec 2027 |
| NCT06358573 | INT230-6 | Phase 2 | Triple-negative Breast Cancer | Oncology | Oct 2028 |
Cash and short-term investments of $8m on 2026-09-30; operating cash outflow about $9m a year; runway about 11 months at that burn, to Sep 2027; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Angiodynamics Can-Fite BioPharma LeonaBio RenovoRx Aura Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.